Bloodborne Pathogens, Infection Control

Total Page:16

File Type:pdf, Size:1020Kb

Bloodborne Pathogens, Infection Control BLOODBORNE PATHOGENS AND INFECTION CONTROL Infectious diseases can be transmitted from person to person. They can be spread through the air, by contact with blood or other body fluids, by touching contaminated surfaces, or by contact with infected wounds. Microscopic organisms that can cause infection are everywhere in the environment, especially in the healthcare setting. To prevent infections from spreading to other patients, healthcare workers, or the community at large, all healthcare workers must understand how bacteria, viruses, and other microorganisms are transmitted that cause infections. Learning Goals: 1. Identify a basic definition of infection control. 2. Identify the most common way microorganisms spread from person to person. 3. Identify three body fluids/secretions that can be infectious. 4. Identify a definition of standard precautions. 5. Identify a definition of universal precautions. 1 Introduction The primary responsibilities for Certified Nursing Assistants (CNAs) is to protect themselves and patients in the healthcare setting. In order to keep patients safe as well as to protect one’s role as a CNA, basic principles of infection control must be understood and carried out. There will be many times when the CNA will care for people with infectious diseases during the course of a career. Unlike some pathologies such as cancer or diabetes, infectious diseases can be transmitted from person to person. They can be spread through the air, by contact with blood or other body fluids, by touching contaminated surfaces, or by contact with infected wounds. Also, microscopic organisms that can cause infection are everywhere in the environment, and they are especially plentiful in the setting of healthcare. In order to prevent these infections from moving to other patients, to the healthcare worker, or to the community at large, it is necessary to understand how bacteria, viruses, and other microorganisms that cause these infections can be transmitted. It is also necessary to know how to work with people who have, or may have, a transmittable disease to avoid becoming infected or infecting others. The Basics Of Disease Transmission Infectious diseases are diseases that can be spread from person to person. They are caused by different types of microorganisms. The basic definition of infection control is: Microorganisms are microscopic life forms A system of techniques used to prevent infections and that cannot be seen and they are, literally, reduce the spread of infections. everywhere. Bacteria and viruses are examples of common microorganisms. They live in the air, in the water, in the soil, and they live in and on our bodies. Microorganisms are found on the skin, lungs, stomach, etc. This sounds 2 unpleasant but many of these microorganisms are actually very helpful. In the stomach and the gastrointestinal tract, they help to digest food. In other parts of the body they help fight infection and help maintain the proper internal environment that the body needs to function. However, there are microorganisms that are not a normal part of the human body internal environment and that can cause illness, and there are microorganisms that do normally live in or on a person but that can cause illness if they are particularly strong or the person is vulnerable. These microorganisms that cause, or can cause illness or disease are called pathogens. Some pathogens such as the virus that causes the flu produce an illness that is relatively mild and rarely causes serious harm. Some pathogens can cause a more serious illness such as pneumonia, but pneumonia can usually be successfully treated with antibiotics. And there are pathogens such as human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). There is no cure for AIDS and no vaccine to prevent infection with HIV. But regardless of how dangerous a pathogen may be, these microorganisms are potentially dangerous because they can move from one person to another. The pathogens are communicable and contagious. They can be spread from the healthcare worker to a patient, they can move from a patient to others, or they can be carried by a healthcare worker from an infected patient to other people. Pathogens that are relatively harmless, such as the flu virus, may even be dangerous if they infect someone who is weak or vulnerable. Someone who has AIDs, someone who has cancer, or a person with diabetes may not be able to contain an infection in the way that normally healthy person would. These patients may suffer serious consequences from a simple infection. 3 There are five basic ways an infection can spread. Some pathogens can only be spread by one of the transmission routes but some can be spread by several. Airborne Transmission Microorganisms are always living in the mouth, the nose, the lungs, and the other parts of the respiratory tract. When someone exhales, talks, sneezes, or coughs, these bacteria and viruses are attached to droplets of moisture and move from the infected person to the air. The infected droplets can move long or short distances, and they can remain suspended in the environment for quite a while or for only a short period of time. How far they move, and how long they stay suspended in the air differs with each microorganism. The risk, of course, is that a dangerous pathogen will move far enough and stay in the air long enough for it to enter the respiratory tract of someone in the area and cause harm. Chicken pox, measles, and tuberculosis are common diseases that have airborne transmission. Influenza can also be spread by airborne transmission, but this method of transmission is limited to short distances of approximately three feet or so. Blood Transmission Pathogens such as hepatitis B, hepatitis C, and HIV are spread by contact with infected blood. This can happen if a healthcare worker is stuck by a needle or splashed with blood in the eyes, mouth, or nose. It can also happen if blood-contaminated medical equipment that is used for more than one patient is not properly cleaned and sterilized, or if the equipment is used improperly, i.e., if a single-use, disposable medical item is used twice. 4 People who use intravenous (IV) drugs and share needles are at high risk for blood transmission of pathogens. Blood transmission can occur through the skin, but only if there is an abrasion or a cut, an entry port for the microorganism. The eyes, mouth, and nose have mucous membranes. These are much more porous than the surface of the skin and bacteria and viruses can easily pass through them and reach the circulation. Contact Transmission Contact transmission of a microorganism occurs when someone has direct contact with the infectious agent. This contact may be simple skin-to-skin contact such as touching a contaminated wound or a contaminated object. Contact transmission is one of the ways that the cold and the influenza viruses are transmitted. These viruses are expelled when an infected person breathes, coughs, or sneezes and the virus settles on objects in the environment, objects such as a computer keyboard, a doorknob, or a telephone receiver. An uninfected person will touch that object, touch his/her nose or mouth and the virus enters the respiratory tract. Other relatively common diseases that are spread through contact transmission are hepatitis A (contact with infected stool), methicillin- resistant staphylococcus aureus (commonly known as MRSA), and many microorganisms that contaminate wounds. Contact transmission of a pathogen is possible by contact with almost any infected body fluid, i.e., blood, mucous, semen; sweat and tears are not generally considered to be high-risk body fluids and contact transmission of a pathogen from these fluids would be very unlikely. Droplet Transmission Droplet transmission could be considered to be a mix of airborne transmission and contact transmission. Droplet transmission occurs when an 5 infected person breathes, coughs, sneezes, or talks and small droplets that are contaminated enter the air and are breathed in by other people. Droplet transmission can also happen during medical procedures such as suctioning. Most experts feel that droplet transmission only occurs within an area of three feet from an infected person, although some people feel the distance may be up to 10 feet. Diseases that can be spread by droplet transmission include influenza, mumps, and pertussis, a.k.a. whooping cough. Sexual Transmission Herpes, HIV, gonorrhea, hepatitis C (possibly), syphilis, chlamydia, and other Contact transmission is easily overlooked. Viruses and diseases can be spread during sexual bacteria live everywhere and even brief and casual contact contact. These contacts can be male-to- with something that is contaminated is enough for a female, female-to-male, male-to-male, microorganism to move from that object or body fluid to you. and female-to-female. The sexual contact And even brief and casual can be anal, oral, or vaginal. contact between you and someone else may be enough to spread that bacteria or virus to So, infectious pathogens are everywhere the patient. in the environment and there are many ways they can be spread. It might seem surprising then that most of us are healthy most of the time. However, for disease transmission to occur the proper conditions must be in place. Movement of a microorganism from one person is just the first step in the development of in infection. For the infection to progress to the development of an infectious illness that produces signs and symptoms, the following factors have to be in place. • The microorganism must be capable of causing an illness; it must be a pathogen • The pathogen must be strong enough to cause an illness; it must be virulent 6 • The pathogen must be strong enough to resist the immune system • There must be a sufficient number of the pathogens • The pathogen must move from person-to-person; transmission mechanism • There must be an entry point - airborne, blood, sexual contact, etc.
Recommended publications
  • REALM Research Briefing: Vaccines, Variants, and Venitlation
    Briefing: Vaccines, Variants, and Ventilation A Briefing on Recent Scientific Literature Focused on SARS-CoV-2 Vaccines and Variants, Plus the Effects of Ventilation on Virus Spread Dates of Search: 01 January 2021 through 05 July 2021 Published: 22 July 2021 This document synthesizes various studies and data; however, the scientific understanding regarding COVID-19 is continuously evolving. This material is being provided for informational purposes only, and readers are encouraged to review federal, state, tribal, territorial, and local guidance. The authors, sponsors, and researchers are not liable for any damages resulting from use, misuse, or reliance upon this information, or any errors or omissions herein. INTRODUCTION Purpose of This Briefing • Access to the latest scientific research is critical as libraries, archives, and museums (LAMs) work to sustain modified operations during the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. • As an emerging event, the SARS-CoV-2 pandemic continually presents new challenges and scientific questions. At present, SARS-CoV-2 vaccines and variants in the US are two critical areas of focus. The effects of ventilation-based interventions on the spread of SARS-CoV-2 are also an interest area for LAMs. This briefing provides key information and results from the latest scientific literature to help inform LAMs making decisions related to these topics. How to Use This Briefing: This briefing is intended to provide timely information about SARS-CoV-2 vaccines, variants, and ventilation to LAMs and their stakeholders. Due to the evolving nature of scientific research on these topics, the information provided here is not intended to be comprehensive or final.
    [Show full text]
  • Reinforcing the Immunocompromised Host Defense Against Fungi: Progress Beyond the Current State of the Art
    Journal of Fungi Review Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art Georgios Karavalakis 1, Evangelia Yannaki 1,2 and Anastasia Papadopoulou 1,* 1 Hematology Department-Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, “George Papanikolaou” Hospital, 57010 Thessaloniki, Greece; [email protected] (G.K.); [email protected] (E.Y.) 2 Department of Medicine, University of Washington, Seattle, WA 98195, USA * Correspondence: [email protected]; Tel.: +30-2313-307-693; Fax: +30-2313-307-521 Abstract: Despite the availability of a variety of antifungal drugs, opportunistic fungal infections still remain life-threatening for immunocompromised patients, such as those undergoing allogeneic hematopoietic cell transplantation or solid organ transplantation. Suboptimal efficacy, toxicity, development of resistant variants and recurrent episodes are limitations associated with current antifungal drug therapy. Adjunctive immunotherapies reinforcing the host defense against fungi and aiding in clearance of opportunistic pathogens are continuously gaining ground in this battle. Here, we review alternative approaches for the management of fungal infections going beyond the state of the art and placing an emphasis on fungus-specific T cell immunotherapy. Harnessing the power of T cells in the form of adoptive immunotherapy represents the strenuous protagonist of the current immunotherapeutic approaches towards combating invasive fungal infections. The progress that has been made over the last years in this field and remaining challenges as well, will be discussed. Citation: Karavalakis, G.; Yannaki, E.; Papadopoulou, A. Reinforcing the Keywords: fungal infections; fungus-specific T cells; T cell immunotherapy Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art.
    [Show full text]
  • A Predictive Modelling Framework for COVID-19 Transmission to Inform the Management of Mass Events
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.13.21256857; this version posted May 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . A Predictive Modelling Framework for COVID-19 Transmission to Inform the Management of Mass Events Claire Donnat Freddy Bunbury Department of Statistics Department of Plant Biology University of Chicago, Chicago, USA Carnegie Institution for Science, Stanford, USA [email protected] [email protected] Jack Kreindler Filippos T. Filippidis School of Public Health School of Public Health Imperial College, London, UK Imperial College, London, UK [email protected] [email protected] Austen El-Osta Tõnu Esko Matthew Harris School of Public Health Institute of Genomics School of Public Health Imperial College, London, UK University of Tartu, Tartu, Estonia Imperial College, London, UK [email protected] [email protected] [email protected] Abstract Modelling COVID-19 transmission at live events and public gatherings is essential to evaluate and control the probability of subsequent outbreaks. Model estimates can be used to inform event organizers about the possibility of super-spreading and the predicted efficacy of safety protocols, as well as to communicate to participants their personalised risk so that they may choose whether to attend. Yet, despite the fast-growing body of literature on COVID transmission dynamics, current risk models either neglect contextual information on vaccination rates or disease prevalence or do not attempt to quantitatively model transmission, thus limiting their potential to provide insightful estimates.
    [Show full text]
  • From the COCCI Syndemic to the COVID-19 Pandemic
    Scholars Insight Publishers Journal of Epidemiology and Global Health Research Research Article Open Access From the COCCI Syndemic to the COVID-19 Pandemic: A Cautionary Tale Interaction of Metabolic Syndrome, Obesity, Particulate Matter (PM), SARS-CoV-2 and the inflammatory response Clearfield M*, Gayer G, Wagner A, Stevenson T, Shubrook J and Gugliucci A Touro University College of Osteopathic Medicine, California, USA Corresponding Author: Dr. Clearfield M, Touro University Abstract College of Osteopathic Medicine, California, USA. A narrative review of the literature was conducted to determine E-mail id: [email protected] associations between cardiovascular (CV) risk factors associated with the COCCI syndemic (Cardiovascular disease as a result of the Received Date: March 15, 2021; interactions between obesity, climate change and inflammation) and Accepted Date: May 19, 2021; COVID-19. Published Date: May 21, 2021; The COCCI syndemic consists of two health conditions Publisher: Scholars Insight Online Publishers (dysmetabolic obesity and air pollution) that interact via biologic Citation: Clearfield M*, Gayer G, Wagner A, Stevenson T, pathways admixed with social, economic and ecologic drivers Shubrook J and Gugliucci A “From the COCCI Syndemic to augmenting adverse clinical outcomes in excess of either of these the COVID-19 Pandemic: A Cautionary Tale Interaction of health conditions individually. Metabolic Syndrome, Obesity, Particulate Matter (PM), SARS- The comorbidities noted with COVID-19 are in large part aligned CoV-2 and the inflammatory response”. J Epidemiol Glob Health with those traditional risk factors associated with CVD. In addition, Res. 2021; 1:102 when the traditional CV comorbidities are combined with the Copyright: ©2021 Clearfield M.
    [Show full text]
  • Possible Modes of Transmission of Novel Coronavirus SARS-Cov-2
    Acta Biomed 2020; Vol. 91, N. 3: e2020036 DOI: 10.23750/abm.v91i3.10039 © Mattioli 1885 Reviews / Focus on Possible modes of transmission of Novel Coronavirus SARS-CoV-2: a review Richa Mukhra1, Kewal Krishan1, Tanuj Kanchan2 1 Department of Anthropology (UGC Centre of Advanced Study), Panjab University, Sector-14, Chandigarh, India 2 Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India. Abstract: Introduction: The widespread outbreak of the novel SARS-CoV-2 has raised numerous questions about the origin and transmission of the virus. Knowledge about the mode of transmission as well as assess- ing the effectiveness of the preventive measures would aid in containing the outbreak of the coronavirus. Presently, respiratory droplets, physical contact and aerosols/air-borne have been reported as the modes of SARS-CoV-2 transmission of the virus. Besides, some of the other possible modes of transmission are being explored by the researchers, with some studies suggesting the viral spread through fecal-oral, conjunctival secretions, flatulence (farts), sexual and vertical transmission from mother to the fetus, and through asymp- tomatic carriers, etc. Aim: The primary objective was to review the present understanding and knowledge about the transmission of SARS-CoV-2 and also to suggest recommendations in containing and preventing the novel coronavirus. Methods: A review of possible modes of transmission of the novel SARS-CoV-2 was conducted based on the reports and articles available in PubMed and ScienceDirect.com that were searched using keywords, ‘transmission’, ‘modes of transmission’, ‘SARS-CoV-2’, ‘novel coronavirus’, and ‘COVID-19’. Articles refer- ring to air-borne, conjunctiva, fecal-oral, maternal-fetal, flatulence (farts), and breast milk transmission were included, while the remaining were excluded.
    [Show full text]
  • Chapter 2 Disease and Disease Transmission
    DISEASE AND DISEASE TRANSMISSION Chapter 2 Disease and disease transmission An enormous variety of organisms exist, including some which can survive and even develop in the body of people or animals. If the organism can cause infection, it is an infectious agent. In this manual infectious agents which cause infection and illness are called pathogens. Diseases caused by pathogens, or the toxins they produce, are communicable or infectious diseases (45). In this manual these will be called disease and infection. This chapter presents the transmission cycle of disease with its different elements, and categorises the different infections related to WES. 2.1 Introduction to the transmission cycle of disease To be able to persist or live on, pathogens must be able to leave an infected host, survive transmission in the environment, enter a susceptible person or animal, and develop and/or multiply in the newly infected host. The transmission of pathogens from current to future host follows a repeating cycle. This cycle can be simple, with a direct transmission from current to future host, or complex, where transmission occurs through (multiple) intermediate hosts or vectors. This cycle is called the transmission cycle of disease, or transmission cycle. The transmission cycle has different elements: The pathogen: the organism causing the infection The host: the infected person or animal ‘carrying’ the pathogen The exit: the method the pathogen uses to leave the body of the host Transmission: how the pathogen is transferred from host to susceptible person or animal, which can include developmental stages in the environment, in intermediate hosts, or in vectors 7 CONTROLLING AND PREVENTING DISEASE The environment: the environment in which transmission of the pathogen takes place.
    [Show full text]
  • Guidelines for Management of Opportunistic Infections and Anti Retroviral Treatment in Adolescents and Adults in Ethiopia
    GUIDELINES FOR MANAGEMENT OF OPPORTUNISTIC INFECTIONS AND ANTI RETROVIRAL TREATMENT IN ADOLESCENTS AND ADULTS IN ETHIOPIA Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health July 2007 PART I GUIDELINES FOR MANAGEMENT OF OPPORTUNISTIC INFECTIONS IN ADULTS AND ADOLESCENTS ii Table of Contents Foreword iv Acknowledgement v Acronyms and Abbreviations vi 1. Introduction 1 2. Objectives and Targets 2 2.1. Objectives 2 2.2. Targets 2 3. Management of Common Opportunistic Infections 2 4. Unit 1: Management of OI of the Respiratory System 3 1.1 Bacterial pneumonia 6 1.2 Pneumonia due to Pneumocystis jiroveci. 6 1.3 Pulmonary tuberculosis 7 1.4 Correlation of pulmonary diseases and CD4 count in HIV-infected patients 9 Unit 2: Management of GI Opportunistic Diseases 11 2.1. Dysphagia and odynophagia 11 2.2. Diarrhoea 12 2.3 Peri-anal problems 14 2.4. Peri-anal and/or genital herpes 15 Unit 3: Management of Opportunistic Diseases of the Nervous system 16 3.1. Peripheral neuropathies 17 3.2. Persistent headache with (+/-) neurological manifestations (+/-) seizure 18 3.3. Management of common CNS infections presenting with headache and/or seizure 19 3.3.1. Toxoplasmosis 19 3.3.2 Management of seizure associated with toxoplasmosis and other CNS OIs 21 3.3.3 Cryptococcosis 23 3.3.4 CNS Tuberculosis 25 Unit 4: Management of Skin Disorders 26 4.1 Aetiological Classification of Skin Disorders in HIV disease. 27 4.2 Selected skin conditions in patients with HIV infection 28 4.2.1 Seborrheic dermatitis 28 4.2.2 Pruritic Papular Eruption 29 4.2.3 Kaposi’s Sarcoma 29 Unit 5: Management of Fever 30 5.1 Selected causes of fever in AIDS patients 33 5.1.1 Malaria 33 5.1.2 Visceral Leishmaniasis 33 5.1.3 Sepsis 34 Unit 6: Some Special Conditions in OI Management 35 6.1 Initiating ART in context of an acute OI 35 6.2 When to initiate ART in context of an acute OI 36 iii Tables 1.
    [Show full text]
  • Intersecting Infections of Public Health Significance Page I Intersecting Infections of Public Health Significance
    Intersecting Infections of Public Health Significance Page i Intersecting Infections of Public Health Significance The Epidemiology of HIV, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis in King County 2008 Intersecting Infections of Public Health Significance was supported by a cooperative agreement from the Centers for Disease Control and Prevention Published December 2009 Alternate formats of this report are available upon request Intersecting Infections of Public Health Significance Page ii David Fleming, MD, Director Jeffrey Duchin, MD, Director, Communicable Disease Epidemiology & Immunization Program Matthew Golden, MD, MPH, Director, STD Program Masa Narita, MD, Director, TB Program Robert Wood, MD, Director, HIV/AIDS Program Prepared by: Hanne Thiede, DVM, MPH Elizabeth Barash, MPH Jim Kent, MS Jane Koehler, DVM, MPH Other contributors: Amy Bennett, MPH Richard Burt, PhD Susan Buskin, PhD, MPH Christina Thibault, MPH Roxanne Pieper Kerani, PhD Eyal Oren, MS Shelly McKeirnan, RN, MPH Amy Laurent, MSPH Cover design and formatting by Tanya Hunnell The report is available at www.kingcounty.gov/health/hiv For additional copies of this report contact: HIV/AIDS Epidemiology Program Public Health – Seattle & King County 400 Yesler Way, 3rd Floor Seattle, WA 98104 206-296-4645 Intersecting Infections of Public Health Significance Page iii Table of Contents INDEX OF TABLES AND FIGURES ········································································ vi EXECUTIVE SUMMARY ······················································································
    [Show full text]
  • Microbial Risk Assessment Guideline
    EPA/100/J-12/001 USDA/FSIS/2012-001 MICROBIAL RISK ASSESSMENT GUIDELINE PATHOGENIC MICROORGANISMS WITH FOCUS ON FOOD AND WATER Prepared by the Interagency Microbiological Risk Assessment Guideline Workgroup July 2012 Microbial Risk Assessment Guideline Page ii DISCLAIMER This guideline document represents the current thinking of the workgroup on the topics addressed. It is not a regulation and does not confer any rights for or on any person and does not operate to bind USDA, EPA, any other federal agency, or the public. Further, this guideline is not intended to replace existing guidelines that are in use by agencies. The decision to apply methods and approaches in this guideline, either totally or in part, is left to the discretion of the individual department or agency. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Environmental Protection Agency (EPA) (2012). Microbial Risk Assessment Guideline: Pathogenic Microorganisms with Focus on Food and Water. EPA/100/J-12/001 Microbial Risk Assessment Guideline Page iii TABLE OF CONTENTS Disclaimer .......................................................................................................................... ii Interagency Workgroup Members ................................................................................ vii Preface ............................................................................................................................. viii Abbreviations ..................................................................................................................
    [Show full text]
  • Opportunistic Infections Moorine Sekadde, Mbchb Heidi Schwarzwald, MD, MPH
    HIV Curriculum for the Health Professional Opportunistic Infections Moorine Sekadde, MBchB Heidi Schwarzwald, MD, MPH Objectives Overview 1. Define opportunistic infections (OIs) in people with Many people living with human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS. (HIV)/AIDS acquire diseases that also affect otherwise 2. Describe primary prophylaxis to prevent OIs in healthy people. In such cases, HIV-infected patients people with HIV/AIDS. may have a more severe disease course than uninfected 3. Evaluate the clinical manifestations of bacterial, people or may develop symptoms that uninfected viral, parasitic, and fungal OIs in people with HIV/ people do not. However, HIV-infected people are also AIDS. susceptible to opportunistic infections (OIs), which 4. Describe the treatment for bacterial, viral, parasitic, are infections caused by organisms that in a healthy and fungal OIs in people with HIV/AIDS. host would not cause significant disease. This module 5. Review specific interventions that can decrease the discusses both types of infection. The most common OIs development of OIs in people with HIV/AIDS. vary with geographic location. This module will give a broad overview of the concepts of preventing OIs and Key Points will discuss the most commonly diagnosed diseases worldwide. The module will cover specific diseases, how to 1. An OI is caused by organisms that would not recognize them, and which medicines are recommended produce significant disease in a person with a well- to treat them. Treatment recommendations are based functioning immune system. on available information and research. Not every 2. People with HIV/AIDS are susceptible to OIs because recommendation will be feasible in every setting.
    [Show full text]
  • Prevention of Hospital-Acquired Infections World Health Organization
    WHO/CDS/CSR/EPH/2002.12 Prevention of hospital-acquired infections A practical guide 2nd edition World Health Organization Department of Communicable Disease, Surveillance and Response This document has been downloaded from the WHO/CSR Web site. The original cover pages and lists of participants are not included. See http://www.who.int/emc for more information. © World Health Organization This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. The mention of specific companies or specific manufacturers' products does no imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. WHO/CDS/CSR/EPH/2002.12 DISTR: GENERAL ORIGINAL: ENGLISH Prevention of hospital-acquired infections A PRACTICAL GUIDE 2nd edition Editors G. Ducel, Fondation Hygie, Geneva, Switzerland J. Fabry, Université Claude-Bernard, Lyon, France L. Nicolle, University of Manitoba, Winnipeg, Canada Contributors R. Girard, Centre Hospitalier Lyon-Sud, Lyon, France M. Perraud, Hôpital Edouard Herriot, Lyon, France A. Prüss, World Health Organization, Geneva, Switzerland A. Savey, Centre Hospitalier Lyon-Sud, Lyon, France E. Tikhomirov, World Health Organization, Geneva, Switzerland M. Thuriaux, World Health Organization, Geneva, Switzerland P. Vanhems, Université Claude Bernard, Lyon, France WORLD HEALTH ORGANIZATION Acknowledgements The World Health Organization (WHO) wishes to acknowledge the significant support for this work from the United States Agency for International Development (USAID).
    [Show full text]
  • Review of Airborne Antimicrobial Resistance
    Title of report (limited to 10 words) Report – XXXXXX/R (project code number) Review of airborne antimicrobial resistance We are the Environment Agency. We protect and improve the environment. Acting to reduce the impacts of a changing climate on people and wildlife is at the heart of everything we do. We reduce the risks to people, properties and businesses from flooding and coastal erosion. We protect and improve the quality of water, making sure there is enough for people, businesses, agriculture and the environment. Our work helps to ensure people can enjoy the water environment through angling and navigation. We look after land quality, promote sustainable land management and help protect and enhance wildlife habitats. And we work closely with businesses to help them comply with environmental regulations. We can’t do this alone. We work with government, local councils, businesses, civil society groups and communities to make our environment a better place for people and wildlife. Published by: Author(s): Environment Agency, Horizon House, Deanery Road, Matt Jones Bristol, BS1 5AH Dissemination status: http://www.gov.uk/government/organisations/environme Publicly available nt-agency Environment Agency’s Project Manager: ISBN: 978-1-84911-424-0 Alwyn Hart, Research, Analysis and Evaluation © Environment Agency – February 2020 All rights reserved. This document may be reproduced with prior permission of the Environment Agency. Further copies of this report are available from our publications catalogue: http://www.gov.uk/government/publications For our National Customer Contact Centre: T: 03708 506506 Email: [email protected] ii Review of airborne antimicrobial resistance Evidence at the Environment Agency Scientific research and analysis underpins everything the Environment Agency does.
    [Show full text]